|Bid||0.00 x 1300|
|Ask||0.00 x 2200|
|Day's range||6.89 - 7.28|
|52-week range||2.43 - 48.48|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.58|
The best defense during a market downturn is usually a good offense. Here are two high-growing cannabis companies that are likely to continue their momentum.
Today, we'll look at which of the two leading companies in the marijuana sector, Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY), is a better buy right now. During the first quarter of 2020, Tilray recognized $52.1 million in revenue, a rise of 126% year over year. Although that growth is spectacular, the company is not profitable -- it recorded a net loss of $184 million, largely due to non-cash adjustments to the fair value of its warrants.
If you think the stock market has had a wild go of things lately, take a gander at marijuana stocks over the past three years. Until the end of the first quarter of 2019, pot stocks were virtually unstoppable. It was not uncommon for cannabis stocks to have delivered triple-digit or quadruple-digit gains to their shareholders.
Tilray, Inc., ("Tilray" or the "Company") (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today announced that management will participate in the following upcoming virtual investor events:
Despite recent troubles, Canopy Growth is optimistic its cannabis beverages can dwarf the growth of hard seltzers.
Shares of Canopy growth (CGC) are trading 30% lower since its latest quarterly results last week. However one analyst sees share as undervalued for the Canadian cannabis company which has shifted from medical to more recreational sales when that market was legalized in Canada almost two years ago. “Although we expect the medical market to shrink because of recreational legalization, we forecast more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers,” analyst Kristoffer Inton wrote in a note to investors.
A pair of marijuana stocks, Tilray (NASDAQ: TLRY) and OrganiGram Holdings (NASDAQ: OGI), both dropped notably in price on Friday (by 5.2% and 7%, respectively). The culprit seems to be another weed title, Canopy Growth (NYSE: CGC), which earlier in the day published an awful quarterly earnings release. Canopy Growth is a leading company in the sector.
Tilray, Inc. ("Tilray" or the "Company") (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced its wholly-owned subsidiary Tilray Portugal, Unipessoal Lda. ("Tilray Portugal") has received a Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal. The GMP certification was issued by Infarmed, the Portuguese National Authority of Medicines and Health Products which provides end-to-end GMP certification for Tilray’s current operations in Portugal.
Tilray, Inc. ("Tilray" or "the Company") (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced its wholly-owned subsidiary High Park Gardens ("Natura Naturals Inc.") will close its doors over the course of the next six weeks. As a result of the closure, the Company expects to realize annualized net savings of approximately $7.5 million (current production costs net of future 3rd party purchases and ongoing depreciation) and avoid significant ongoing capital expenditures.
Canadian cannabis company Tilray's (NASDAQ: TLRY) CEO believes that at least 12 marijuana companies will go under this year. In March, Tilray announced that it would be raising $90.4 million through an offering, largely because the company still could. CEO Brendan Kennedy told BNN Bloomberg that he "wasn't sure anyone was going to be able to raise any money in this industry again" and that "when we had the opportunity to strengthen the balance sheet, we did."
Ladies and gentlemen, thank you for standing by, and welcome to Tilray's First Quarter 2020 Earnings Conference Call. Good afternoon, and thank you for joining us on Tilray's first quarter 2020 earnings conference call and webcast. On with me today are Brendan Kennedy, Chief Executive Officer; and Michael Kruteck, Chief Financial Officer.
Tilray's (NASDAQ:TLRY) 55% year-to-date loss is, without question, really bad. But it could have been much worse. Actually, it was much worse. At one point in March, Tilray had plunged nearly 90%.
Tilray Inc (TLRY) delivered earnings and revenue surprises of -11.36% and 4.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the first quarter ended March 31, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
What happened Tilray (NASDAQ: TIL) shareholders outperformed a strong market last month. The stock rose 17% compared to a 13% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.